Inside the market of emerging biotech

For nearly a decade, biotech companies and their venture backers enjoyed a historic boom. Although momentum has come to a halt, many of the largest venture investors remain flush with cash, while progress in gene editing, messenger RNA and cell therapies promise new kinds of medicines in the future.

included in this trendline

• ‘Fear and uncertainty’: Biotech investors warn of impact from NIH research cuts

• Blocking PD-1 and VEGF: The bispecific cancer drugs that could best Keytruda

• ‘The bar has risen’: China’s biotech gains push US companies to adapt

Our Trendlines go deep on the biggest trends. These special reports, produced by our team of award-winning journalists, help business leaders understand how their industries are changing.

Inside the market of emerging biotech